Gilenya in new therapeutic indication: Added benefit not proven
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) who had received other pretreatment than interferon beta (IFN-β). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.
According to the findings, such an added benefit is not proven: For some of the patients, the drug manufacturer presented no data. For other patients, the available study data either showed no differences between the treatment groups, or the data were not evaluable............ Read More - http://www.ms-uk.org/gilenya
Gilenya in new therapeutic indication: Added benefit not...
Gilenya in new therapeutic indication: Added benefit not...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1659 Views
-
Last post by Petr75
-
- 0 Replies
- 1292 Views
-
Last post by jimmylegs
-
- 0 Replies
- 787 Views
-
Last post by ElliotB
-
- 0 Replies
- 1484 Views
-
Last post by CureIous
-
- 5 Replies
- 13330 Views
-
Last post by gibbledygook